Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Measles mumps and rubella virus vaccine - GlaxoSmithKline

Drug Profile

Measles mumps and rubella virus vaccine - GlaxoSmithKline

Alternative Names: 209762; GSK-209762; MMR vaccine - Bio-Manguinhos; MMR vaccine - GlaxoSmithKline; Priorix; SB-209762

Latest Information Update: 11 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Measles vaccines; Rubella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Measles; Mumps; Rubella

Most Recent Events

  • 11 Feb 2019 Launched for Measles (Prevention) in Taiwan (SC)
  • 11 Feb 2019 Launched for Mumps (Prevention) in Taiwan (SC)
  • 11 Feb 2019 Launched for Rubella (Prevention) in Taiwan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top